A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
| Image |  |
|---|---|
| Description | scientific article published on 12 February 2018 |
| Author/s |
author: Seock-Ah Im Xavier Pivot Tomasz Sarosiek Marek Wojtukiewicz |
| Publication date | February 12, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |